Quantitative MR relaxometry study of effects of vigabatrin on the brains of patients with epilepsy.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Epilepsy Research

• Publication date

  1994-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0920-1211(94)90005-1PMID 7957035
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of hippocampal pathology in intractable partial epilepsy

  1993cited by this paper
• Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy.

  1992cited by this paper
• Open, Double‐Blind and Long‐Term Study of Vigabatrin in Chronic Epilepsy

  1991cited by this paper
• Effect of lamotrigine on carbamazepine epoxide concentrations

  1991cited by this paper
• Headache, third nerve palsy, and MS

  1991cited by this paper
• Neuropathologic Findings in Patients Receiving Long-Term Vigabatrin Therapy for Chronic Intractable Epilepsy

  1991cited by this paper
• Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles.

  1990cited by this paper
• Chronic Toxicity Studies with Vigabatrin, A GABA-Transaminase Inhibitor

  1990cited by this paper
• Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy.

  1989cited by this paper
• The Neuropathology of Vigabatrin

  1989cited by this paper
• Clinical pharmacology of vigabatrin.

  1989cited by this paper
• Neuropathology of vigabatrin.

  1989cited by this paper
• Precise relaxation time measurements of normal‐appearing white matter in inflammatory central nervous system disease

  1989cited by this paper
• Vigabatrin: no microvacuoles in a human brain.

  1987cited by this paper
• A Study of the Effects of Vigabatrin on the Central Nervous System and Retina of Sprague Dawley and Lister-Hooded Rats

  1987cited by this paper
• Vigabatrin in the Treatment of Epilepsy: A Double‐Blind, Placebo‐Controlled Study

  1986cited by this paper
• Effect of gamma‐vinyl GABA on human pattern evoked visual potentials

  1985cited by this paper
• DOUBLE-BLIND STUDY OF γ-VINYL GABA IN PATIENTS WITH REFRACTORY EPILEPSY

  1984cited by this paper
• Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy.

  1984cited by this paper

• Altered regional brain T2 relaxation times in individuals with chronic orofacial neuropathic pain

  2018cites this paper
• Chapter 14 – Nervous System and Special Sense Organs

  2012cites this paper
• Vigabatrin in Refractory Complex Partial Seizures: The Evidence of its Therapeutic Value

  2010cites this paper
• Cerebral MRI abnormalities associated with vigabatrin therapy

  2009cites this paper
• Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval

  2009cites this paper
• Seizures and Antiepileptic Drugs: Does Exposure Alter Normal Brain Development in Animal Models?

  2009cites this paper
• Nervous System and Special Sense Organs

  2007cites this paper
• Development of vigabatrin‐induced lesions in the rat brain studied by magnetic resonance imaging, histology, and immunocytochemistry

  2004influential citation
• Vigabatrin Visual Toxicity: Evolution and Dose Dependence

  2001cites this paper
• The Potential for Vigabatrin‐Induced Intramyelinic Edema in Humans

  2000cites this paper
• Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group.

  1999cites this paper
• New Antiepileptic Drugs

  1999cites this paper
• „Product-related“ und „Non-product-related“ Processes and Production Methods

  1999cites this paper
• Treatment of Infantile Spasms: Results of a Population‐Based Study with Vigabatrin as the First Drug for Spasms

  1999cites this paper
• Neuroimaging in epilepsy

  1998cites this paper
• A comparison of the neuropathological effects of vigabatrin and carbamazepine in patients with newly diagnosed localization-related epilepsy using MR-based cerebral T2 relaxation time measurements.

  1998cites this paper
• Recurrent seizures may cause hippocambal damage in temporal lobe epilepsy

  1998cites this paper
• Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities.

  1998cites this paper
• [Therapeutic options provided by new antiepileptic drugs].

  1997cites this paper
• Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances.

  1997cites this paper
• Imaging and epilepsy.

  1997cites this paper
• Vigabatrin

  1996cites this paper
• Technique for measuring hippocampal T2 relaxation time.

  1996cites this paper
• Section Review Central & Peripheral Nervous Systems: New anti-epileptic drugs

  1995cites this paper
• Nonsteroidal anti‐inflammatory drugs in Alzheimer's disease

  1995cites this paper
• Vigabatrin in Childhood Epilepsy: A 5-Year Follow-Up Study

  1995cites this paper
• Vigabatrin edema

  1995cites this paper
• New antiepileptic drugs: Prospects for the future

  1995cites this paper
• Vigabatrin

  1995cites this paper
• Newer Antiepileptic Drugs

  1994cites this paper
• MR detection of hippocampal disease in epilepsy: factors influencing T2 relaxation time.

  1994cites this paper